Interstitial Lung Disease Clinical Trials in Cincinnati, Ohio

5 studies are recruiting for interstitial lung disease in Cincinnati, Ohio right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

   This is a prospective, real world, multicenter, registry of patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) and interstitial lung disease (ILD).

   Stage

   Not phased

   Ages

   18 and older

   Site

   University of Cincinnati Medical Center, Cincinnati, Ohio

   Locations

   71 in total

   Run by

   United Therapeutics

   See if you can join NCT06388421 on ClinicalTrials.gov

2. Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

   The primary objective of this study is to evaluate the effect of 24-weeks of once daily treatment with TPIP versus placebo on exercise capacity in adults with PH-ILD.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   USA015, Cincinnati, Ohio

   Locations

   145 in total

   Run by

   Insmed Incorporated

   See if you can join NCT07179380 on ClinicalTrials.gov

3. Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung Disease

   There is no standard of care therapy for patients with granulomatous-lymphocytic interstitial lung disease (GLILD) seen in common variable immunodeficiency (CVID). Abatacept has recently looked promising for the treatment of patients with complex CVID. This study is a multi-site, phase II, randomiz…

   Stage

   Phase 2

   Ages

   4 and older

   Site

   Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio

   Locations

   6 in total

   Run by

   Children's Hospital Medical Center, Cincinnati

   See if you can join NCT04925375 on ClinicalTrials.gov

4. Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)

   Study RIN-PF-305 is designed to evaluate the safety and efficacy of inhaled treprostinil in subjects with progressive pulmonary fibrosis (PPF) over a 52-week period.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   University of Cincinnati Medical Center, Cincinnati, Ohio

   Locations

   165 in total

   Run by

   United Therapeutics

   See if you can join NCT05943535 on ClinicalTrials.gov

5. An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH

   Study LTI-401 is an open-label, multicenter study which will evaluate the safety and tolerability of LIQ861 in subjects who have WHO Group 1 \& 3 PH.

   Stage

   Not phased

   Ages

   18 to 80

   Site

   University of Cincinnati Health, Cincinnati, Ohio

   Locations

   23 in total

   Run by

   Liquidia Technologies, Inc.

   See if you can join NCT06129240 on ClinicalTrials.gov